These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

294 related articles for article (PubMed ID: 26405082)

  • 1. MR Imaging-Based Analysis of Glioblastoma Multiforme: Estimation of IDH1 Mutation Status.
    Yamashita K; Hiwatashi A; Togao O; Kikuchi K; Hatae R; Yoshimoto K; Mizoguchi M; Suzuki SO; Yoshiura T; Honda H
    AJNR Am J Neuroradiol; 2016 Jan; 37(1):58-65. PubMed ID: 26405082
    [TBL] [Abstract][Full Text] [Related]  

  • 2. IDH1 mutation prediction using MR-based radiomics in glioblastoma: comparison between manual and fully automated deep learning-based approach of tumor segmentation.
    Choi Y; Nam Y; Lee YS; Kim J; Ahn KJ; Jang J; Shin NY; Kim BS; Jeon SS
    Eur J Radiol; 2020 Jul; 128():109031. PubMed ID: 32417712
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Noninvasive Prediction of IDH1 Mutation and ATRX Expression Loss in Low-Grade Gliomas Using Multiparametric MR Radiomic Features.
    Ren Y; Zhang X; Rui W; Pang H; Qiu T; Wang J; Xie Q; Jin T; Zhang H; Chen H; Zhang Y; Lu H; Yao Z; Zhang J; Feng X
    J Magn Reson Imaging; 2019 Mar; 49(3):808-817. PubMed ID: 30194745
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Predicting TERT promoter mutation using MR images in patients with wild-type IDH1 glioblastoma.
    Yamashita K; Hatae R; Hiwatashi A; Togao O; Kikuchi K; Momosaka D; Yamashita Y; Kuga D; Hata N; Yoshimoto K; Suzuki SO; Iwaki T; Iihara K; Honda H
    Diagn Interv Imaging; 2019; 100(7-8):411-419. PubMed ID: 30948344
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Noninvasively evaluating the grading and IDH1 mutation status of diffuse gliomas by three-dimensional pseudo-continuous arterial spin labeling and diffusion-weighted imaging.
    Liu T; Cheng G; Kang X; Xi Y; Zhu Y; Wang K; Sun C; Ye J; Li P; Yin H
    Neuroradiology; 2018 Jul; 60(7):693-702. PubMed ID: 29777252
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Combined texture analysis of diffusion-weighted imaging with conventional MRI for non-invasive assessment of IDH1 mutation in anaplastic gliomas.
    Su CQ; Lu SS; Zhou MD; Shen H; Shi HB; Hong XN
    Clin Radiol; 2019 Feb; 74(2):154-160. PubMed ID: 30391048
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Increased sensitivity to radiochemotherapy in IDH1 mutant glioblastoma as demonstrated by serial quantitative MR volumetry.
    Tran AN; Lai A; Li S; Pope WB; Teixeira S; Harris RJ; Woodworth DC; Nghiemphu PL; Cloughesy TF; Ellingson BM
    Neuro Oncol; 2014 Mar; 16(3):414-20. PubMed ID: 24305712
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Whole-Tumor Histogram and Texture Analyses of DTI for Evaluation of
    Park YW; Han K; Ahn SS; Choi YS; Chang JH; Kim SH; Kang SG; Kim EH; Lee SK
    AJNR Am J Neuroradiol; 2018 Apr; 39(4):693-698. PubMed ID: 29519794
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Radiological features combined with IDH1 status for predicting the survival outcome of glioblastoma patients.
    Wang K; Wang Y; Fan X; Wang J; Li G; Ma J; Ma J; Jiang T; Dai J
    Neuro Oncol; 2016 Apr; 18(4):589-97. PubMed ID: 26409566
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Invasion and proliferation kinetics in enhancing gliomas predict IDH1 mutation status.
    Baldock AL; Yagle K; Born DE; Ahn S; Trister AD; Neal M; Johnston SK; Bridge CA; Basanta D; Scott J; Malone H; Sonabend AM; Canoll P; Mrugala MM; Rockhill JK; Rockne RC; Swanson KR
    Neuro Oncol; 2014 Jun; 16(6):779-86. PubMed ID: 24832620
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Noninvasive IDH1 mutation estimation based on a quantitative radiomics approach for grade II glioma.
    Yu J; Shi Z; Lian Y; Li Z; Liu T; Gao Y; Wang Y; Chen L; Mao Y
    Eur Radiol; 2017 Aug; 27(8):3509-3522. PubMed ID: 28004160
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dynamic Contrast-Enhanced T1-Weighted Perfusion Magnetic Resonance Imaging Identifies Glioblastoma Immunohistochemical Biomarkers via Tumoral and Peritumoral Approach: A Pilot Study.
    Ozturk K; Soylu E; Tolunay S; Narter S; Hakyemez B
    World Neurosurg; 2019 Aug; 128():e195-e208. PubMed ID: 31003026
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Glioblastoma with PNET-like components has a higher frequency of isocitrate dehydrogenase 1 (IDH1) mutation and likely a better prognosis than primary glioblastoma.
    Song X; Andrew Allen R; Terence Dunn S; Fung KM; Farmer P; Gandhi S; Ranjan T; Demopoulos A; Symons M; Schulder M; Li JY
    Int J Clin Exp Pathol; 2011; 4(7):651-60. PubMed ID: 22076165
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Morphologic patterns of noncontrast-enhancing tumor in glioblastoma correlate with IDH1 mutation status and patient survival.
    Lasocki A; Gaillard F; Tacey M; Drummond K; Stuckey S
    J Clin Neurosci; 2018 Jan; 47():168-173. PubMed ID: 28988652
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prediction of IDH1 Mutation Status in Glioblastoma Using Machine Learning Technique Based on Quantitative Radiomic Data.
    Lee MH; Kim J; Kim ST; Shin HM; You HJ; Choi JW; Seol HJ; Nam DH; Lee JI; Kong DS
    World Neurosurg; 2019 May; 125():e688-e696. PubMed ID: 30735871
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Isocitrate dehydrogenase-1 mutations as prognostic biomarker in glioblastoma multiforme patients in West Bohemia.
    Polivka J; Polivka J; Rohan V; Pesta M; Repik T; Pitule P; Topolcan O
    Biomed Res Int; 2014; 2014():735659. PubMed ID: 24511544
    [TBL] [Abstract][Full Text] [Related]  

  • 17. IDH1 mutations is prognostic marker for primary glioblastoma multiforme but MGMT hypermethylation is not prognostic for primary glioblastoma multiforme.
    Kalkan R; Atli Eİ; Özdemir M; Çiftçi E; Aydin HE; Artan S; Arslantaş A
    Gene; 2015 Jan; 554(1):81-6. PubMed ID: 25455102
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Reliability of noncontrast-enhancing tumor as a biomarker of IDH1 mutation status in glioblastoma.
    Lasocki A; Tsui A; Gaillard F; Tacey M; Drummond K; Stuckey S
    J Clin Neurosci; 2017 May; 39():170-175. PubMed ID: 28214089
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Differentiating primary CNS lymphoma from glioblastoma multiforme: assessment using arterial spin labeling, diffusion-weighted imaging, and ¹⁸F-fluorodeoxyglucose positron emission tomography.
    Yamashita K; Yoshiura T; Hiwatashi A; Togao O; Yoshimoto K; Suzuki SO; Abe K; Kikuchi K; Maruoka Y; Mizoguchi M; Iwaki T; Honda H
    Neuroradiology; 2013 Feb; 55(2):135-43. PubMed ID: 22961074
    [TBL] [Abstract][Full Text] [Related]  

  • 20. IDH1 mutation may not be prognostically favorable in glioblastoma when controlled for tumor location: A case-control study.
    Paldor I; Drummond KJ; Kaye AH
    J Clin Neurosci; 2016 Dec; 34():117-120. PubMed ID: 27522495
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.